According to the fifth edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [5], 26 patients (93%) were classified as DLBCL-NOS, and 2 patients (7%) were classified as HGBCL with MYC and BCL2 rearrangements. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.